These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36871242)

  • 61. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.
    Joy MS; Matzke GR; Frye RF; Palevsky PM
    Am J Kidney Dis; 1998 Jun; 31(6):1019-27. PubMed ID: 9631848
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy.
    Akers KS; Cota JM; Chung KK; Renz EM; Mende K; Murray CK
    J Burn Care Res; 2012; 33(6):e254-62. PubMed ID: 22878490
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Non-pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy.
    Tsujimoto Y; Miki S; Shimada H; Tsujimoto H; Yasuda H; Kataoka Y; Fujii T
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013330. PubMed ID: 34519356
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Low flucloxacillin concentrations in a patient with central nervous system infection: the need for plasma and cerebrospinal fluid drug monitoring in the ICU.
    Abdul-Aziz MH; McDonald C; McWhinney B; Ungerer JP; Lipman J; Roberts JA
    Ann Pharmacother; 2014 Oct; 48(10):1380-4. PubMed ID: 24951308
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Continuous venovenous hemodiafiltration with a low citrate dose regional anticoagulation protocol and a phosphate-containing solution: effects on acid-base status and phosphate supplementation needs.
    Morabito S; Pistolesi V; Tritapepe L; Vitaliano E; Zeppilli L; Polistena F; Fiaccadori E; Pierucci A
    BMC Nephrol; 2013 Oct; 14():232. PubMed ID: 24156306
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients.
    Guenter SG; Iven H; Boos C; Bruch HP; Muhl E
    Pharmacotherapy; 2002 Feb; 22(2):175-83. PubMed ID: 11837556
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Continuous venovenous hemofiltration after coronary procedures for the prevention of contrast-induced acute kidney injury in patients with severe chronic renal failure.
    Guastoni C; Bellotti N; Poletti F; Covella P; Gidaro B; Stasi A; Seveso G; D'Urbano M; Mariani M; De Servi S
    Am J Cardiol; 2014 Feb; 113(4):588-92. PubMed ID: 24321895
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Levetiracetam Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemofiltration and Venoarterial Extracorporeal Membrane Oxygenation.
    Nei SD; Wittwer ED; Kashani KB; Frazee EN
    Pharmacotherapy; 2015 Aug; 35(8):e127-30. PubMed ID: 26242293
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure.
    Lonnemann G; Bechstein M; Linnenweber S; Burg M; Koch KM
    Kidney Int Suppl; 1999 Nov; (72):S84-7. PubMed ID: 10560813
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases.
    Pea F; Viale P; Lugano M; Pavan F; Scudeller L; Della Rocca G; Furlanut M
    Am J Kidney Dis; 2004 Dec; 44(6):1097-102. PubMed ID: 15558532
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regional citrate anticoagulation in predilution continuous venovenous hemofiltration using prismocitrate 10/2 solution.
    Shum HP; Chan KC; Yan WW
    Ther Apher Dial; 2012 Feb; 16(1):81-6. PubMed ID: 22248200
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetics of flucloxacillin and its metabolites in patients with renal failure: Impact on liver toxicity
.
    Maier-Salamon A; Elgendy SA; Meyer B; Vossen M; Thalhammer T; Thalhammer F; Jäger W
    Int J Clin Pharmacol Ther; 2017 Sep; 55(9):701-711. PubMed ID: 28737131
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Continuous venovenous hemofiltration in severely burned patients with acute kidney injury: a cohort study.
    Chung KK; Lundy JB; Matson JR; Renz EM; White CE; King BT; Barillo DJ; Jones JA; Cancio LC; Blackbourne LH; Wolf SE
    Crit Care; 2009; 13(3):R62. PubMed ID: 19409089
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Analysis of Leukocyte Recruitment in Continuous Veno-Venous Hemofiltration with Regional Citrate vs. Systemic Heparin Anticoagulation.
    Margraf A; Liu C; Küllmar M; Meersch M; Rossaint J; Zarbock A
    Cells; 2022 Jun; 11(11):. PubMed ID: 35681510
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High unbound flucloxacillin fraction in critically ill patients.
    Wallenburg E; Ter Heine R; de Lange DW; van Leeuwen H; Schouten JA; Ten Oever J; Kolwijck E; Burger DM; Pickkers P; Gieling EM; de Maat MM; Frenzel T; Brüggemann RJ
    J Antimicrob Chemother; 2021 Nov; 76(12):3220-3228. PubMed ID: 34463730
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.
    Monchi M; Berghmans D; Ledoux D; Canivet JL; Dubois B; Damas P
    Intensive Care Med; 2004 Feb; 30(2):260-265. PubMed ID: 14600809
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration.
    Radej J; Krouzecky A; Stehlik P; Sykora R; Chvojka J; Karvunidis T; Novak I; Matejovic M
    Ther Drug Monit; 2011 Aug; 33(4):393-7. PubMed ID: 21654349
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations?
    Wong G; Briscoe S; Adnan S; McWhinney B; Ungerer J; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6165-70. PubMed ID: 24080664
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lacosamide Pharmacokinetics in a Critically Ill Patient During Continuous Renal Replacement Therapy.
    Wieruszewski PM; Lopez-Ruiz A; Albright RC; Fugate JE; Barreto EF
    J Pharm Pract; 2020 Jun; 33(3):395-398. PubMed ID: 30336720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.